Literature DB >> 31512743

A Prospective Study Identifying Predictive Factors of Cardiac Decompensation After Transjugular Intrahepatic Portosystemic Shunt: The Toulouse Algorithm.

Chloé Billey1, Sophie Billet2, Marie Angèle Robic1, Thomas Cognet2, Maeva Guillaume1, Jean Pierre Vinel1, Jean Marie Péron1, Olivier Lairez2, Christophe Bureau1.   

Abstract

BACKGROUND AND AIMS: Transjugular intrahepatic portosystemic shunt (TIPS) is now a standard for the treatment of portal hypertension-related complications. After the TIPS procedure, incidence and risk factors of cardiac decompensation are poorly known. The main objectives were to measure the incidence of the onset of cardiac decompensation after TIPS and identify the predictive factors. APPROACH AND
RESULTS: All patients with cirrhosis treated with TIPS between May 2011 and June 2016 were considered for inclusion. They received a cardiac assessment by standard biological parameters, transthoracic echocardiography, and right heart catheterization. Patients were followed for 1 year after TIPS insertion. The main endpoint was the incidence of cardiac decompensation requiring hospitalization. One hundred seventy-four patients were treated by TIPS during the period. One hundred patients who underwent a complete cardiac evaluation were included. A cardiac decompensation occurred in 20% of the patients. The parameters associated with the occurrence of severe cardiac decompensation were a prolonged QT interval corrected (462 vs. 443 ms; P = 0.05), an elevated pre-TIPS brain natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-proBNP) level, an elevated E/A ratio (1.5 vs. 1.0; P = 0.001) and E/e' ratio (11 vs. 7; P < 0.001), and a left atrial dilatation (40 vs. 29 mL/m2 ; P = 0.011). The presence of aortic stenosis was also associated with cardiac decompensation. A level of BNP <40 pg/mL and NT-proBNP <125 pg/mL allowed identifying patients without risk of cardiac decompensation. Additionally, absence of diastolic dysfunction criteria at echocardiography ruled out the risk of further cardiac decompensation.
CONCLUSIONS: Hospitalization for cardiac decompensation is observed in 20% of patients in the year after TIPS insertion. Combining BNP or NT-proBNP levels and echocardiographic parameters should help improve patient selection.
© 2019 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31512743     DOI: 10.1002/hep.30934

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  17 in total

1.  Assessment of Clinical Outcomes, Clinical Manifestations, and Risk Factors for Hepatic Infarction After Transjugular Intrahepatic Portosystemic Shunt Placement (TIPS): A Retrospective Comparative Study.

Authors:  Tisileli S Tuifua; Sasan Partovi; Erick M Remer; Jonathan Ragheb; Jennifer A Bullen; Michael W Kattan; Baljendra Kapoor
Journal:  Cardiovasc Intervent Radiol       Date:  2022-07-18       Impact factor: 2.797

Review 2.  Imaging-guided interventions modulating portal venous flow: Evidence and controversies.

Authors:  Roberto Cannella; Lambros Tselikas; Fréderic Douane; François Cauchy; Pierre-Emmanuel Rautou; Rafael Duran; Maxime Ronot
Journal:  JHEP Rep       Date:  2022-04-04

Review 3.  Management of Liver Decompensation in Advanced Liver Disease (Renal Impairment, Liver Failure, Adrenal Insufficiency, Cardiopulmonary Complications).

Authors:  Luis Téllez; Antonio Guerrero
Journal:  Clin Drug Investig       Date:  2022-05-06       Impact factor: 3.580

Review 4.  Where does TIPS fit in the management of patients with cirrhosis?

Authors:  Juan Carlos García-Pagán; Saad Saffo; Mattias Mandorfer; Guadalupe Garcia-Tsao
Journal:  JHEP Rep       Date:  2020-05-23

Review 5.  Current Concepts of Cirrhotic Cardiomyopathy.

Authors:  Manhal J Izzy; Lisa B VanWagner
Journal:  Clin Liver Dis       Date:  2021-03-10       Impact factor: 6.126

Review 6.  Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020.

Authors:  Adelina Horhat; Christophe Bureau; Dominique Thabut; Marika Rudler
Journal:  United European Gastroenterol J       Date:  2021-02-23       Impact factor: 4.623

7.  Cardiovascular magnetic resonance demonstrates structural cardiac changes following transjugular intrahepatic portosystemic shunt.

Authors:  Ulf K Radunski; Johannes Kluwe; Malte Klein; Antonio Galante; Gunnar K Lund; Christoph Sinning; Sebastian Bohnen; Enver Tahir; Jitka Starekova; Peter Bannas; Christian Stehning; Gerhard Adam; Ansgar W Lohse; Stefan Blankenberg; Kai Muellerleile; Daniel Benten
Journal:  Sci Rep       Date:  2021-06-16       Impact factor: 4.379

8.  Risk Factors of Atrial Arrhythmia in Patients With Liver Cirrhosis: A Retrospective Study.

Authors:  Xiya Lu; Zhijing Wang; Liu Yang; Changqing Yang; Meiyi Song
Journal:  Front Cardiovasc Med       Date:  2021-07-05

Review 9.  North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension.

Authors:  Justin R Boike; Bartley G Thornburg; Sumeet K Asrani; Michael B Fallon; Brett E Fortune; Manhal J Izzy; Elizabeth C Verna; Juan G Abraldes; Andrew S Allegretti; Jasmohan S Bajaj; Scott W Biggins; Michael D Darcy; Maryjane A Farr; Khashayar Farsad; Guadalupe Garcia-Tsao; Shelley A Hall; Caroline C Jadlowiec; Michael J Krowka; Jeanne Laberge; Edward W Lee; David C Mulligan; Mitra K Nadim; Patrick G Northup; Riad Salem; Joseph J Shatzel; Cathryn J Shaw; Douglas A Simonetto; Jonathan Susman; K Pallav Kolli; Lisa B VanWagner
Journal:  Clin Gastroenterol Hepatol       Date:  2021-07-15       Impact factor: 13.576

10.  Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension.

Authors:  Dhiraj Tripathi; Adrian J Stanley; Peter C Hayes; Simon Travis; Matthew J Armstrong; Emmanuel A Tsochatzis; Ian A Rowe; Nicholas Roslund; Hamish Ireland; Mandy Lomax; Joanne A Leithead; Homoyon Mehrzad; Richard J Aspinall; Joanne McDonagh; David Patch
Journal:  Gut       Date:  2020-02-29       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.